Login to Your Account

Jennerex's $8.6M Financing Boosts Cancer Pipeline

By Catherine Shaffer

Friday, August 12, 2011
Jennerex Inc. completed a private placement of $8.6 million in gross proceeds to support development of its lead cancer candidate, JX-594. The product, an oncolytic virus, has shown antitumor activity in Phase I and Phase II trials, with demonstrated overall survival benefit in advanced liver cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription